Nutrition in pediatric cardiomyopathy

Progress in Pediatric Cardiology

Volumn 24, Issue 1, 2007, Pages 59-71

  Miller, Tracie L ^a   Neri, Daniela ^a   Extein, Jason ^a   Somarriba, Gabriel ^a   Strickman Stein, Nancy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Ancillary therapy; Nutrition; Pediatric cardiomyopathy

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CARNITINE; CREATINE; RETINOL; TAURINE; THIAMINE; TRACE ELEMENT; UBIQUINONE;

CARDIOMYOPATHY; ENERGY YIELD; HEART FAILURE; HEART FUNCTION; HUMAN; MACRONUTRIENT; NUTRIENT; NUTRITION; NUTRITIONAL STATUS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 35348909033     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2007.08.007     Document Type: Review

References (126)

1. Nugent A.W., Daubeney P.E., Chondros P., et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 348 17 (Apr 24 2003) 1639-1646
2. Lipshultz S.E., Sleeper L.A., Towbin J.A., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 348 17 (Apr 24 2003) 1647-1655
3. Grenier M.A., Osganian S.K., Cox G.F., et al. Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J 139 2 Pt 3 (2000) S86-S95
4. Boucek M.M., Faro A., Novick R.J., et al. The Registry of the International Society of Heart and Lung Transplantation: Fourth Official Pediatric Report-2000. J Heart Lung Transplant 20 (2001) 39-52
5. Colan S.D., Spevak P.J., Parness I.A., et al. Cardiomyopathies. In: Fyler D.C. (Ed). Nadas' Pediatric Cardiology (1992), Balfus and Hanley, New York
6. Burch M., Siddiqi S.A., Celermajer D.D., et al. Dilated cardiomyopathy in children: determinants of outcome. Br Heart J 72 (1994) 246-250
7. Maron B.J., Tajik A.J., Ruttenberg H.D., et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 65 1 (1982) 7-17
8. Towbin J.A., and Bowles N.E. The failing heart. Nature 415 6868 (Jan 10 2002) 227-233
9. Thiene G., Becker A.E., Buja L.M., et al. Toward a cardiovascular pathology training report on the forum held in Vancouver, March 6, 2004, Society for Cardiovascular Pathology. Cardiovasc Pathol 14 6 (Nov Dec 2005) 312-319
10. Boucek M.M., Edwards L.B., Keck B.M., et al. The Registry of the International Society for Heart and Lung Transplantation: Sixth Official Pediatric Report-2003. J Heart Lung Transplant 22 (2003) 636-652
11. Bilgic A., Ozbarlas N., Ozkutlu S., et al. Cardiomyopathies in children: clinical, epidemiological and prognostic evaluation. Jpn Heart J 31 (1990) 789-797
12. Lipshultz S.E. Ventricular dysfunction clinical research in infants, children and adolescents. Prog Pediatr Cardiol 12 1 (Nov 4 2000) 1-28
13. Evans R.W. Economic and social costs of heart transplantation. Heart Transplant 1 (1982) 243-251
14. Strauss A., and Lock J.E. Pediatric cardiomyopathy-a long way to go. N Engl J Med 348 17 (Apr 24 2003) 1703-1705
15. Blecker U., Mehta D.I., Davis R., et al. Nutritional problems in patients who have chronic disease. Pediatr Rev 21 1 (2000) 29-32
16. Karp R.J., Bachrach S.J., and Moskowitz S. Malnutrition in chronic illness of childhood with special reference to pulmonary disease. Clin Chest Med 1 3 (1980) 375-383
17. Kelly D.A. Nutrition and growth in patients with chronic liver disease. Indian J Pediatr 62 5 (1995) 533-544
18. Kohaut E.C. Chronic renal disease and growth in childhood. Curr Opin Pediatr 7 2 (1995) 171-175
19. Yip R., and Scanlon K. The burden of malnutrition: a population perspective. J Nutr 10 (2002) 2043s-2046s [supplement]
20. Franssen F.M., Wouters E.F., and Schols A.M. The contribution of starvation deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 21 1 (2002) 1-14
21. Keusch G.T. The history of nutrition: malnutrition, infection, and immunity. J Nutr 133 1 (2003) 336s-340s
22. Hughes W.T., Price R.A., Sisko F., et al. Protein-calorie malnutrition. A host determinant for Pneumocystis carnii. Am J Dis Child 128 1 (1974) 44-52
23. Miller T.L., Awnetwant E.L., Evans S., et al. Gastrostomy tube supplementation fo HIV-infected children. Pediatrics 96 (1995) 696-702
24. Al-Attar I., Orav E.J., Exil V., et al. Pedictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. J Am Coll Cardiol 41 9 (2003) 1598-1605
25. Azevedo V.M., Albanesi-Filho F.M., Santos M.A., et al. The impact of malnutrition on idiopathic dilated cardiomyopathy in children. J Pediatr (Rio J) 80 3 (2004) 211-216 [Portuguese]
26. Leitch C.A. Growth, nutrition and energy expenditure in pediatric heart failure. Prog Pediatr Cardiol 11 3 (2000) 195-202
27. Miller T.L., Orav E.J., Colan S.D., and Lipshultz S.E. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 66 3 (Sep 1997) 660-664
28. Davos C.H., Doehner W., Rauchhaus M., et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 9 1 (Feb 2003) 29-35
29. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., and Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 3 (Sep 2001) 789-795
30. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, Fluoride (1997). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12 (1998). Dietary Reference Intakes for vitamin C, Vitamin E, Selenium, and Carotenoids (2000).Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2001). Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (2002). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate (2004). Food and Nutrition Board, Institute of Medicine, National Academies of Sciences. Retrieved June 20, 2007 from http://www.nap.edu.
31. Linde L.M. Psychiatric aspects of congenital heart disease. Psychiatr Clin North Am 5 (1982) 399-406
32. Howard B.V., Van Horn L., Hsia J., et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Moification Trial. JAMA 295 6 (Feb 8 2006) 655-666
33. Sparagna G.C., Hickson-Bick D.L., Buja L.M., and McMillin J.B. A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 279 5 (Nov 2000) H2124-H2132
34. Gudz T.I., Tserng K.Y., and Hoppel C.L. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 272 39 (Sep 26 1997) 24154-24158
35. Okere I.C., Young M.E., McElfresh T.A., et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension 48 6 (Dec 2006) 1116-1123 [Electronic publication 2006 Oct 23]
36. Broqvist M., Arnqvist H., Dahlstrom U., Larsson J., Nylander E., and Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure: effects of long-term dietary supplementation. Eur Heart J 15 (1994) 1641-1650
37. Sole M.J., and Jeejeebhoy K.N. Conditioned nutritional requirements: therapeutic relevance to heart failure. Herz 27 (2002) 174-179 [PubMed SpringerLink]
38. de Lorgeril M., and Salen P. Diet as preventive medicine in cardiology. Curr Opin Cardiol 15 5 (Sep 2000) 364-370
39. Keith M., Geranmayegan A., Sole M.J., et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31 6 (May 1998) 1352-1356
40. Kris-Etherton P.M., Harris W.S., and Appel L.J. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 21 (Nov 19 2002) 2747-2757 [No abstract available. Erratum in: Circulation. 2003 Jan 28;107(3):512]
41. Kaul N., Siveski-Iliskovic N., Hill M., Slezak J., and Singal P.K. Free radicals and the heart. J Pharmacol Toxicol Methods 30 2 (Oct 1993) 55-67
42. Prasad K., Kalra J., and Bharadwaj L. Cardiac depressant effects of oxygen free radicals. Angiology 44 4 (Apr 1993) 257-270
43. Dhalla A.K., and Singal P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 266 4 Pt 2 (Apr 1994) H1280-H1285
44. Gupta M., and Singal P.K. Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res 64 2 (Feb 1989) 398-406
45. Li R.K., Sole M.J., Mickle D.A., Schimmer J., and Goldstein D. Vitamin E and oxidative stress in the heart of the cardiomyopathic Syrian hamster. Free Radic Biol Med 24 (1997) 252-258
46. Carlson D., Maass D.L., White D.J., Tan J., and Horton J.W. Antioxidant vitamin therapy alters sepsis-related apoptotic myocardial activity and inflammatory responses. Am J Physiol Heart Circ Physiol 291 6 (Dec 2006) H2779-H2789
47. Montessuit C., Papageorgiou I., Campos L., and Lerch R. Retinoic acids increase expression of GLUT4 in dedifferentiated and hypertrophied cardiac myocytes. Basic Res Cardiol 101 1 (Jan 2006) 27-35
48. Palace V.P., Khaper N., Qin Q., and Singal P.K. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med 26 (1999) 746-761
49. Miwa K., Kishimoto C., Nakamura H., et al. Serum thioredoxin and alpha-tocopherol concentrations in patients with major risk factors. Circ J 69 (2005) 291-294
50. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 154-160
51. Lonn E., Yusuf S., Hoogwerf B., et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25 (2002) 1919-1927
52. Lonn E., Bosch J., Yusuf S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (2005) 1338-1347
53. Mann J.F., Lonn E.M., Yi Q., et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65 (2004) 1375-1380
54. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
55. Keith M.E., Jeejeebhoy K.N., Langer A., et al. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am J Clin Nutr 73 (2001) 219-224
56. Azuma J., Sawamura A., and Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ 56 (1992) 95-99
57. Schuller-Levis G.B., and Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 226 (2003) 195-202
58. Grimble R.F., Jackson A.A., Persaud C., Wride M.J., Delers F., and Engler R. Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet. J Nutr 122 (1992) 2066-2073
59. Schaffer S.W., Allo S., Harada H., and Mozaffari M. Potentation of myocardial ischemic injury by drug-induced taurine depletion. In: Huxtable R.J., Franconi F., and Giotti A. (Eds). The biology of taurine (1987), New York: Plenum Press 151-158
60. Kramer J.H., Chovan J.P., and Schaffer S.W. The effect of taurine on calcium paradox and ischemic heart failure. Am J Physiol 240 (1981) H238-H246
61. Oudit G.Y., Trivieri M.G., Khaper N., et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron overload murine model. Circulation 109 (2004) 1877-1885
62. Kishi T., Okamoto T., Takahashi T., Goshima K., and Yamagami T. Cardiostimulatory action of coenzyme Q homologues on cultured myocardial cells and their biochemical mechanisms. Clin Investig 71 8 Suppl (1993) S71-S75
63. Bentinger M., Dallner G., Chojnacki T., and Swiezewska E. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med 34 5 (Mar 1 2003) 563-575
64. Shindo Y., Witt E., Han D., Epstein W., and Packer L. Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin. Invest Dermatol 102 (1994) 122-124
65. Kitamura N., Yamaguchi A., and Otaki M. Myocardial tissue level of co-enzyme Q10 in patients with cardiac failure. In: Folkers K., and Yamamura Y. (Eds). Biomedical and physical aspects of coenzyme Q vol. 4 (1984), Elsevier, Amsterdam 243-257
66. Jameson S. Statistical data support prediction of death within 6 months on low levels of coenzyme Q10 and other entities. Clin Invest 71 (1993) S137-S139
67. Hofman-Bang C., Rehnqvist N., Swedberg K., et al. Coenzyme Q10 as an adjunctive treatment of chronic congestive heart failure. The Q10 study group. J Card Fail 2 (1995) 101-107
68. Morisco C., Trimarco B., and Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicentre randomised study. Clin Invest 71 (1993) S134-S136
69. Watson P.S., Scalia G.M., Galbraith A., et al. Lack of effect of coenzyme Q10 on left ventricular function in patients with congestive cardiac failure. J Am Coll Cardiol 33 (1999) 1549-1552
70. Khatta M., Alexander B.S., Krichten C.M., et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 132 (2000) 636-640
71. Permanetter B., Rossy W., Klein G., et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 13 (1992) 1528-1533
72. 10 illuminated by meta-analysis of clinical trials. Mol Aspects Med 18 (1997) S159-S168 [Suppl]
73. de Lorgeril M., Salen P., Accominotti M., et al. Dietary and blood antioxidants in patients with chronic heart failure. Insights into the potential importance of selenium in heart failure. Eur J Heart Fail 3 (2001) 661-669
74. Guaiquil V.H., Golde D.W., Beckles D.L., Mascareno E.J., and Siddiqui M.A. Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic Biol Med 37 (2004) 1419-1429
75. Fu Y.C., Chi C.S., Yin S.C., Hwang B., Chiu Y.T., and Hsu S.L. Norepinephrine induces apoptosis in neonatal rat cardiomyocytes through a reactive oxygen species-TNF alpha-caspase signaling pathway. Cardiovasc Res 62 (2004) 558-566
76. Rossig L., Hoffmann J., Hugel B., et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 104 (2001) 2182-2187
77. Qin F., Yan C., Patel R., Liu W., and Dong E. Vitamins C and E attenuate apoptosis, beta-adrenergic receptor desensitization, and sarcoplasmic reticular Ca2+ ATPase downregulation after myocardial infarction. Free Radic Biol Med 40 10 (May 15 2006) 1827-1842
78. Shi W., Meininger C.J., Haynes T.E., Hatakeyama K., and Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem Biophys 41 (2004) 415-434
79. Enstrom J.E., Kanim L.E., and Klein M.A. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3 (1992) 194-202
80. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 23-33
81. Erbs S., Gielen S., Linke A., et al. Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. Am Heart J 146 2 (Aug 2003) 280-285
82. Seligmann H., Halkin H., Rauchfleisch S., et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med 91 (1991) 151-155
83. Zenuk C., Healey J., Donnelly J., Vaillancourt R., Almalki Y., and Smith S. Thiamine deficiency in congestive heart failure patients receiving long-term furosemide therapy. Can J Clin Pharmacol 10 (2003) 184-188
84. Brady J.A., Rock C.L., and Horneffer M.R. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc 95 (1995) 541-544
85. Kwok T., Falconer-Smith J.F., Potter J.F., and Ives D.R. Thiamine status of elderly patients with cardiac failure. Age Ageing 21 (1992) 67-71
86. Pfitzenmeyer P., Guilland J.C., d'Athis P., Petit-Marneier C., and Gaudet M. Thiamine status of elderly patients with cardiac failure including the effects of supplements. Int J Vitam Nutr Res 64 (1994) 113-118
87. Yue Q.Y., Beerman B., Lindstrom B., and Nyquist O. No difference in blood thiamine diphosphate levels between Swedish Caucasians patients with congestive heart failure treated with furosemide and patients without heart failure. J Intern Med 242 (1997) 491-495
88. Mendoza C.E., Rodriguez F., and Rosenberg D.G. Reversal of refractory congestive heart failure after thiamine supplementation: a case report and review of the literature. J Cardiovasc Pharmacol Ther 8 (2003) 313-316
89. Arsenian M.A. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40 (1997) 265-286
90. Schonekess B.O., Allard M.F., and Lopaschuk G.D. Propionyl l-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77 (1995) 726-734
91. Engel A.G., and Rebouche C.J. Carnitine metabolism and inborn errors. J Inherit Metab Dis 7 Suppl 1 (1984) 38-43
92. Pepine C.J. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 13 (1991) 2-18
93. Whitmer J.T. l-carnitine treatment improves cardiac performance and restores high-phosphate pools in cardiomyopathic Syrian hamster. Circ Res 61 (1987) 396-408
94. Iliceto S., Scrutinio D., Bruzzi P., et al. Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. Am Coll Cardiol 26 (1995) 380-387
95. Risos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J 139 (2000) S120-S123
96. Nascimben L., Ingwall J.S., Pauletto P., et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation 94 (1996) 1894-1901
97. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997) 2190-2196
98. Pulido S.M., Passaquin A.C., Leijendekker W.J., et al. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett 439 (1998) 357-362
99. Balsom P.D., Soderlund K., and Ekblom B. Creatine in humans with special reference to creatine supplementation. Sports Med 18 (1994) 268-280
100. Casey A., Constantin-Teodosiu D., Howell S., et al. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. Am J Physiol 271 (1996) E31-E37
101. Andrews R., Grenhaff P., Curtis S., Perry A., and Cowley A.J. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 19 (1998) 617-622
102. Weisshaar R.E., and Simpson R.U. Involvement of vitamin D3 with cardiovascular function. Direct and indirect effects. Am J Physiol 253 (1987) E675-E683
103. Witte K.K., Desilva R., Chattopadhyay S., Ghosh J., Cleland J.G., and Clark A.L. Are hematinic deficiencies the cause of anemia in chronic heart failure?. Am Heart J 147 (May 2004) 924-930
104. Gorelik O., Almoznino-Sarafian D., Feder I., et al. Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 99 (2003) 177-181
105. Andersson S.E., Edvinsson M.L., and Edvinsson L. Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity. Basic Clin Pharmacol Toxicol 97 (2005) 306-310
106. Andersson S.E., Edvinsson M.L., and Edvinsson L. Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity. Basic Clin Pharmacol Toxicol 97 (2005) 306-310
107. Wester P.O., and Dyckner T. Intracellular electrolytes in cardiac failure. Acta Med Scand Suppl 707 (1986) 33-36
108. Milionis H.J., Alexandrides G.E., Liberopoulos E.N., Bairaktari E.T., Goudevenos J., and Elisaf M.S. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail 4 (2002) 167-173
109. Cohen N., Almoznino-Sarafian D., Zaidenstein R., et al. Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. Heart 89 (2003) 411-416
110. Haigney M.C., Berger R., Schulman S., et al. Tissue magnesium levels and the arrhythmic substrate in humans. J Cardiovasc Electrophysiol 8 (1997) 980-986
111. Gottlieb S.S., Baruch L., Kukin M.L., et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 16 (1990) 827-831
112. Eichorn E.J., Tandon P.K., and Di Bianco R. Clinical and prognostic significance of serum magnesium concentration in patients with severe CCF: the PROMISE study. J Am Coll Cardiol 21 (1993) 634-640
113. Wester P.O. Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol 70 (1992) 44-49C
114. Gottlieb S.S. Importance of magnesium in congestive heart failure. Am J Cardiol 63 (1989) 39-42G
115. Strassburger M., Bloch W., Sulyok S., et al. Heterozygous deficiency of manganese superoxide dismutase results in severe lipid peroxidation and spontaneous apoptosis in murine myocardium in vivo. Free Radic Biol Med 38 (2005) 1458-1470
116. Golik A., Zaidenstein R., Dishi V., et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr 17 (1998) 75-78
117. Koren-Michowitz M., Dishy V., Zaidenstein R., et al. The effect of losartan and losartan/hydrochlorothiazide fixed-combination on magnesium, zinc, and nitric oxide metabolism in hypertensive patients: a prospective open-label study. Am J Hypertens 18 (2005) 358-363
118. Arthur J.R., Nicol F., Mitchell J.H., et al. Selenium and iodine deficiencies and selenoprotein function. Biomed Environ Sci 10 (1997) 129-135
119. Levander O.A. A global view of human selenium nutrition. Annu Rev Nutr 7 (1987) 227-250
120. Schnabel R., Lackner K.J., Rupprecht H.J., et al. Glutathione peroxidase 1 activity and homocysteine for cardiovascular risk prediction. Results from the Athero Gene Study. J Am Coll Cardiol 45 (2005) 1631-1637
121. Wu H.Y., Xia Y.M., Ha P.C., and Chen X.S. Changes in myocardial thyroid hormone metabolism and alpha-glycerophosphate activity in rats deficient in iodine and selenium. Br J Nutr 78 (1997) 671-676
122. Blankenberg S., Rupprecht H.J., Bickel C., et al. Glutathione peroxidase activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349 (2003) 1605-1613
123. Reeves W.C., Marchuard S.P., Willis S.E., et al. Reversible cardiomyopathy due to selenium deficiency. J Parent Enter Nutr 13 (1989) 663-665
124. Kien C.L., and Ganther H.E. Manifestations of chronic selenium deficiency in a child receiving total parenteral nutrition. Am J Clin Nutr 37 (1983) 319-321
125. Gramm H.J., Kopf A., and Brätter P. The necessity of selenium substitution in total parenteral nutrition and artificial alimentation. J Trace Elem Med Biol 9 (1995) 1-12
126. Darling G., Mathias P., Oregan M., et al. Serum selenium levels in individuals on PKU diets. J Inherit Metab Dis 87 (1991) 339